Searching for Wegovy 7.5mg? Here's What That Dose Actually Is

You searched for 7.5mg (and you're not the only one

Picture this: you've been reading about Wegovy, you've seen a number somewhere) in a forum post, a news article, maybe a WhatsApp message from a friend, and the figure that stuck was 7.5mg. It sounds plausible. The jump from 2.4mg to a higher dose feels like the kind of news that would get rounded up in casual conversation. But the licensed UK dose is 7.2mg, and that 0.3mg difference isn't rounding, it's a separate regulatory fact.

The MHRA approved the 7.2mg maintenance dose for semaglutide (Wegovy) initially in January 2026 as three 2.4mg pens used in the same week, and then on 14 April 2026 approved a dedicated single-dose 7.2mg pen, one pre-set weekly injection with an auto-dosing mechanism and built-in covered needle that locks after use. The MHRA's announcement on GOV.UK confirms the approval date and the specific pen design. No 7.5mg version exists. No 7.3mg. No 7.4mg. The next licensed step above 2.4mg is 7.2mg exactly.

It's a small thing, but searching for the wrong number can land you in the wrong place, including sellers who might not notice (or care) that the dose you're asking about doesn't appear on any licensed packaging. That's worth keeping in mind before you make any decisions.

What the Wegovy dosing schedule actually looks like from the start

The Wegovy titration route matters because no one starts at 7.2mg. The schedule prescribed under the NHS's semaglutide guidance begins at 0.25mg for the first four weeks, a starting dose designed to ease your body into treatment, then moves through 0.5mg, 1.0mg and 1.7mg before reaching the original 2.4mg maintenance dose, each step roughly four weeks apart, guided by how well you're tolerating the previous dose. The 7.2mg step is above 2.4mg and is for patients who have been on the maintenance dose and for whom a higher dose is clinically appropriate.

The purpose of the slow start isn't therapeutic in itself; the early doses are about letting your system adjust. Nausea, the most common early side effect, is far more manageable when the dose goes up gradually. Jumping ahead doesn't speed up weight loss, it mostly just increases the likelihood of feeling rough. A prescriber decides when, and if, moving up makes sense for you specifically. You can read more about how the full schedule works on the Wegovy doses overview if you want the broader picture. For comparison, the 5mg step sits between earlier stages and 2.4mg in a different semaglutide context, the Wegovy injection ladder uses the steps above.

The 7.2mg pen is licensed for adults with a BMI of 30 or above for the weight management indication. It is not currently licensed for the cardiovascular risk indication at that dose. Your starting point, regardless of which dose you eventually reach, is always 0.25mg.

What the evidence says about 7.2mg, and why 7.5mg comparisons online may be misleading

The trial data behind the 7.2mg dose is genuinely noteworthy. Novo Nordisk reported roughly 20.7% average weight loss over 72 weeks at this dose, which narrows the gap with tirzepatide 15mg considerably compared with the 2.4mg semaglutide results from the STEP 1 trial, which showed around 15% average reduction. That STEP 1 figure was itself a landmark result when published, so 20.7% represents a meaningful step forward for the semaglutide programme.

If you've seen 7.5mg mentioned alongside these kinds of results online, it's likely either a misremembering or, less charitably, a number attached to something that isn't a licensed UK product. Any seller quoting a 7.5mg Wegovy dose is either misinformed or isn't dealing in licensed medicines. The practical consequence: if you were hoping to get a higher Wegovy dose than 2.4mg, the dose you actually want to ask about is 7.2mg, and whether it's appropriate is a clinical judgement. Have a look at the Wegovy overview for the full picture on the medicine before you go further.

Cost is a real consideration too. If you're weighing up options, the Wegovy price comparison page sets out what private treatment typically costs and what a legitimate price should include, which might be useful context before your consultation.

Getting the right information before any clinical conversation

One thing our prescribers hear fairly often is that people arrive at a consultation having read a lot (forums, Facebook groups, health journalists who mixed up Wegovy and Ozempic dose numbers) and feel confident they know what they need, but the number they've fixed on turns out not to match what's licensed. That's not a problem; it's just a conversation. But it does mean that going in with the correct terminology helps.

The dose you're likely thinking of, if you've heard that Wegovy now goes higher than 2.4mg, is 7.2mg. Whether you'd be eligible to reach that dose, and how long that titration would take, depends on your full clinical picture: your BMI (the licence applies at BMI 30 or above), your current weight trajectory, and how you've tolerated earlier doses. Some people do fine at 2.4mg and don't need to go further. Others find the additional dose makes the difference. There's no single answer that applies to everyone, which is exactly why the prescriber review matters, it's not a formality before a tick-box, it's the actual decision point. Treatment is a prescription-only process in the UK, and the prescriber decides the dose, not the patient's internet search. If you'd like to explore whether Wegovy is the right option for you, and want to understand what the 1.5mg stage of the titration involves before your consultation, speak to our prescribers through a free consultation, same day, clinically reviewed by a real person.